Form 4: VolitionRx CEO Reports RSU Vesting and Share Disposition

VolitionRx's CEO of Volition Veterinary, Salvatore Thomas Butera, reported the vesting of 53,400 restricted stock units and the disposition of 99,350 common shares.

Summary

• Salvatore Thomas Butera, CEO of Volition Veterinary at VOLITIONRX LTD (VNRX), reported changes in his beneficial ownership.
• On January 22, 2026, 53,400 restricted stock units (RSUs) vested due to the achievement of certain corporate performance goals.
• These 53,400 RSUs, part of an original 178,000 RSU award from March 17, 2025, are subject to a further 3-year time-based vesting schedule, with 17,800 units vesting on March 17, 2026, 2027, and 2028, respectively.
• The reporting person disposed of 99,350 shares of common stock, which were jointly owned with his spouse.
• Following these reported transactions, Mr. Butera's direct beneficial ownership stands at 375,203 shares of common stock.
• The remaining 124,600 RSUs from the original award did not vest and were cancelled on June 30, 2025, and January 22, 2026.

Sentiment

Score: 5

Explanation: Neutral. The filing reports routine insider transactions, including both RSU vesting (positive for management compensation) and share disposition (neutral, could be for various personal reasons), and some RSU cancellations (slight negative for performance targets).

Positives

• 53,400 restricted stock units (RSUs) vested due to the achievement of corporate performance goals, indicating successful operational milestones.

Negatives

• The reporting person disposed of 99,350 shares of common stock.
• 124,600 restricted stock units (RSUs) did not vest and were cancelled, indicating some performance goals were not met.

Future Outlook

The 53,400 vested RSUs are subject to a future 3-year time-based vesting schedule, with installments on March 17, 2026, 2027, and 2028, indicating future share issuances to the reporting person upon meeting these time conditions.

Industry Context

This Form 4 reports routine insider transactions related to executive compensation and personal portfolio management. It does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: The vesting of RSUs aligns management incentives with shareholder value. The disposition of shares by an executive is a routine event and its impact depends on the context and scale, generally considered neutral unless it signals a significant change in insider sentiment.
• Management: The vesting of RSUs represents a component of the CEO's compensation, aligning their interests with company performance.

Next Steps

• The 53,400 vested RSUs will convert into common stock in three equal installments of 17,800 units on March 17, 2026, 2027, and 2028, upon meeting time-based vesting conditions.

Key Dates

Keywords

VolitionRx, VNRX, SEC Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Share Disposition, Salvatore Thomas Butera, CEO, Volition Veterinary, Beneficial Ownership